{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:53:03Z","timestamp":1770771183541,"version":"3.50.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10147-019-01476-0","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T15:14:11Z","timestamp":1559402051000},"page":"1320-1327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-9269","authenticated-orcid":false,"given":"Masaya","family":"Hattori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumitaka","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruru","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Tatematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Tachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Hijioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Andoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunari","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Sawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyo","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Gondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"issue":"9637","key":"1476_CR1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(08)61039-9","journal-title":"Lancet"},{"issue":"6","key":"1476_CR2","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514\u2013523. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1009290","journal-title":"N Engl J Med"},{"issue":"6","key":"1476_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520\u2013529. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"issue":"10022","key":"1476_CR4","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(10022):968\u2013977. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)00817-X","journal-title":"Lancet"},{"issue":"4","key":"1476_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.oraloncology.2012.11.008","volume":"49","author":"F Martins","year":"2013","unstructured":"Martins F, de Oliveira MA, Wang Q et al (2013) A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 49(4):293\u2013298. \n                    https:\/\/doi.org\/10.1016\/j.oraloncology.2012.11.008","journal-title":"Oral Oncol"},{"issue":"3","key":"1476_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/annonc\/mdv595","volume":"27","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, Hortobagyi GN, Yao J et al (2016) Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol 27(3):519\u2013525. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv595","journal-title":"Ann Oncol"},{"key":"1476_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30109-2","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Seneviratne L, Beck JT et al (2017) Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(17)30109-2","journal-title":"Lancet Oncol"},{"key":"1476_CR8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0340","author":"VE Jones","year":"2019","unstructured":"Jones VE, McIntyre KJ, Paul D et al (2019) Evaluation of miracle mouthwash plus hydrocortisone versus prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: a randomized phase II study. Oncologist. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2018-0340","journal-title":"Oncologist"},{"issue":"10","key":"1476_CR9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30(10):870\u2013884. \n                    https:\/\/doi.org\/10.1007\/s12325-013-0060-1","journal-title":"Adv Ther"},{"issue":"6","key":"1476_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s12282-013-0444-8","volume":"21","author":"S Noguchi","year":"2014","unstructured":"Noguchi S, Masuda N, Iwata H et al (2014) Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer 21(6):703\u2013714. \n                    https:\/\/doi.org\/10.1007\/s12282-013-0444-8","journal-title":"Breast Cancer"},{"issue":"4","key":"1476_CR11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/annonc\/mdu009","volume":"25","author":"HS Rugo","year":"2014","unstructured":"Rugo HS, Pritchard KI, Gnant M et al (2014) Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 25(4):808\u2013815. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdu009","journal-title":"Ann Oncol"},{"issue":"10","key":"1476_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/jjco\/hys123","volume":"42","author":"T Ito","year":"2012","unstructured":"Ito T, Okusaka T, Ikeda M et al (2012) Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn J Clin Oncol 42(10):903\u2013911. \n                    https:\/\/doi.org\/10.1093\/jjco\/hys123","journal-title":"Jpn J Clin Oncol"},{"key":"1476_CR13","doi-asserted-by":"publisher","unstructured":"Toi M, Masuda N, Andre F et al (2013) Everolimus plus trastuzumab and vinorelbine in Asian patients with HER2-positive metastatic breast cancer. In: Thirty-sixth annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio. \n                    https:\/\/doi.org\/10.1158\/0008-5472.sabcs13-p4-12-19\n                    \n                  . Published December 2013","DOI":"10.1158\/0008-5472.sabcs13-p4-12-19"},{"key":"1476_CR14","doi-asserted-by":"publisher","unstructured":"Toyama T, Jeong J, Srimuninnimit V et al (2017) Everolimus (EVE)+ letrozole (LET) in Asian patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2\u2212) advanced breast cancer (ABC): results of a subgroup analysis from the BOLERO-4 study. In: ESMO Asia, Singapore. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx654","DOI":"10.1093\/annonc\/mdx654"},{"issue":"4","key":"1476_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs18-p1-11-01","volume":"79","author":"N Niikura","year":"2019","unstructured":"Niikura N, Nakatukasa K, Amamiya T, Watanabe K-i, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Horii K, Hayashi N, Naito M, Kashiwabara K, Yamashita T, Umeda M, Mukai H, Ota Y (2019) Abstract P1\u201311-01: oral care evaluation to prevent oral mucositis in estrogen receptor positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): a randomized controlled phase III trial. Cancer Res 79(4):P1-11-01-P11-11-01. \n                    https:\/\/doi.org\/10.1158\/1538-7445.sabcs18-p1-11-01","journal-title":"Cancer research"},{"issue":"4","key":"1476_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0030-4220(90)90376-4","volume":"69","author":"ST Sonis","year":"1990","unstructured":"Sonis ST, Tracey C, Shklar G et al (1990) An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 69(4):437\u2013443","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"9 Suppl","key":"1476_CR17","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/cncr.20163","volume":"100","author":"EB Rubenstein","year":"2004","unstructured":"Rubenstein EB, Peterson DE, Schubert M et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026\u20132046. \n                    https:\/\/doi.org\/10.1002\/cncr.20163","journal-title":"Cancer"},{"key":"1476_CR18","volume-title":"Adrenal cortical steroids. Drug facts and comparisons","author":"KH Steven","year":"1997","unstructured":"Steven KH (1997) Adrenal cortical steroids. Drug facts and comparisons, 5th edn. Facts and Comparisons, Inc., St. Louis","edition":"5"},{"issue":"1","key":"1476_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cncr.24696","volume":"116","author":"S Sonis","year":"2010","unstructured":"Sonis S, Treister N, Chawla S et al (2010) Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116(1):210\u2013215. \n                    https:\/\/doi.org\/10.1002\/cncr.24696","journal-title":"Cancer"},{"issue":"1","key":"1476_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1634\/theoncologist.2011-0111","volume":"17","author":"CB Boers-Doets","year":"2012","unstructured":"Boers-Doets CB, Epstein JB, Raber-Durlacher JE et al (2012) Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 17(1):135\u2013144. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2011-0111","journal-title":"Oncologist"},{"issue":"2","key":"1476_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000438747","volume":"8","author":"TF Meiller","year":"2015","unstructured":"Meiller TF, Varlotta S, Weikel D (2015) Recognition and management of oral mucosal injury caused by mammalian target of rapamycin inhibitors: a case series. Case Rep Oncol 8(2):369\u2013377. \n                    https:\/\/doi.org\/10.1159\/000438747","journal-title":"Case Rep Oncol"},{"issue":"8","key":"1476_CR22","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/cam4.761","volume":"5","author":"DE Peterson","year":"2016","unstructured":"Peterson DE, O\u2019Shaughnessy JA, Rugo HS et al (2016) Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med 5(8):1897\u20131907. \n                    https:\/\/doi.org\/10.1002\/cam4.761","journal-title":"Cancer Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01476-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01476-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01476-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T23:27:47Z","timestamp":1590881267000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01476-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01476-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]},"assertion":[{"value":"30 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Masaya Hattori received honoraria from Chugai Pharmaceutical, Eli Lilly Japan, Novartis Pharma, AstraZeneca, Pfizer Japan, and Eisai for work performed outside of the current study. Susumu Hijioka received honoraria from Novel Pharma, Novartis Pharma, and Tenjin Pharma for work performed outside of the current study. Hiroji Iwata received research funding from Chugai Pharmaceutical, MSD K.K, Eli Lilly Japan, and Novartis Pharma for work performed outside of the current study; received honoraria from Chugai Pharmaceutical, Daiichi Sankyo, and AstraZeneca for work performed outside of the current study; and is a member of scientific advisory board of Daiichi Sankyo, Chugai Pharmaceutical, Eli Lilly Japan, Kyowa Hakko Kirin, Pfizer Japan, Novartis Pharma, and AstraZeneca for work performed outside of the current study. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}